Chiba Refractory Schizophrenia Treatment-LAI study

Conditions

schizophrenia,schizoaffective disorder

Hiroshi Kimura, Nobuhisa Kanahara, Tsuyoshi Sasaki, Naoya Komatsu, Minoru Ishige et al. (14 authors)

Journal of Psychopharmacology2016-07-0127 citations

A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis

Hiroshi Kimura, Nobuhisa Kanahara, Naoya Komatsu, Minoru Ishige, Katsumasa Muneoka et al. (20 authors)

Schizophrenia Research2014-03-2354 citations

10.1016/j.schres.2014.02.022

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The diagnosis of schizophrenia or schizoaffective disorder was based on the diagnostic and statistical manual of mental disorders fourth edition text revision.TRS was defined as a failure to respond to at least two antipsychotics belonging to two different chemical classes at dosages equivalent to or greater than 600 mg/day of chlorpromazine for at least 4 weeks and the global assessment of functioning scale 60 or less in the preceding 1 year, or the presence of tardive diskinesia.

Exclusion criteria

Exclusion criteria: Patients who have already received risperidone long- acting injection.

Design outcomes

Primary

Measure	Time frame
Brief Psychiatric Rating Scale	—

Countries

Japan

Contacts

Public ContactNobuhisa Kanahara,Hiroshi Kimura

Graduate School of Medicine, Chiba University Department of Psychiatry

Outcome results